Table 5.
Performance of biomarkers for prognosis of overall survival.
| Below Cutoff | Above Cutoff | |||||
|---|---|---|---|---|---|---|
| Cutoff | Median OS (d) | 95% CI | Median OS (d) | 95% CI | p-Value | |
| Pretherapeutic | ||||||
| HMGB1 | 2.84 | 195 | 116–274 | 239 | 165–313 | 0.742 |
| CEA | 5.50 | 180 | 140–220 | 211 | 140–282 | 0.896 |
| CYFRA 21-1 | 4.90 | 291 | 10–572 | 139 | 73–205 | 0.001 |
| Prior to cycle 2 | ||||||
| HMGB1 | 2.52 | 239 | 89–389 | 184 | 51–317 | 0.038 |
| CEA | 5.60 | 195 | 147–233 | 211 | 12–410 | 0.888 |
| CYFRA 21-1 | 4.40 | 643 | 438–848 | 134 | 86–182 | <0.001 |
| Prior to cycle 3 | ||||||
| HMGB1 | 2.69 | 490 | 296–684 | 134 | 98–170 | <0.001 |
| CEA | 6.00 | 279 | 30 -528 | 242 | 130–354 | 0.721 |
| CYFRA 21-1 | 3.85 | 624 | 399–849 | 167 | 103–231 | <0.001 |
Kaplan–Meier and Log-Rank analyses show of the prognostic value of biomarkers in NSCLC patients if median is used as cutoff. Median overall survival (OS) in days (d) with 95% confidence intervals (CI) is given for the group with values below and above the cutoff. Significance as calculated according Log-Rank analysis. Cutoffs are given in ng/mL. p-values in bold indicate statistically significant results. HMGB1: high mobility group box 1 protein, CEA: carcinoembryonic antigen, CYFRA 21-1: cytokeratin 19-fragments.